Market Place
Sourcing Support
CNS Pharmaceuticals Updates on Berubicin Study in GBM
25 Nov 2024 //
ACCESSWIRE
CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin
17 Jan 2024 //
ACCESSWIRE
CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
18 Dec 2023 //
ACCESSWIRE
CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin
22 Nov 2023 //
ACCESSWIRE
CNS Pharmaceuticals` Ongoing Potentially Pivotal Study of Berubicin
11 Oct 2023 //
ACCESSWIRE
CNS Reaches Milestone with Enrollment of 200 Patients in Study of Berubicin
07 Sep 2023 //
ACCESSWIRE
CNS Pharmaceuticals Presents Results from Pivotal Study of Berubicin
14 Aug 2023 //
ACCESSWIRE
CNS Pharmaceuticals Provides Clinical Trial Update for Study with Berubicin
03 Aug 2023 //
ACCESSWIRE
CNS Achieves Over 50% Completion of Enrollment in Study with Berubicin for GBM
25 May 2023 //
ACCESSWIRE
Patients Enrolled in CNS Pharmac’ Pivotal Study Evaluating Berubicin
10 Apr 2023 //
ACCESSWIRE
CNS Pharmaceuticals Receives Approval for Berubicin for the Treatment of GBM
06 Apr 2023 //
ACCESSWIRE
CNS Continues Momentum in Potentially Pivotal Global Trial Evaluating Berubicin
09 Mar 2023 //
PR NEWSWIRE
CNS Announces First Patient Enrolled in Spain in Trial Evaluating Berubicin
07 Feb 2023 //
PR NEWSWIRE
CNS doses first subject in brain cancer treatment trial in France
02 Nov 2022 //
CLINICALTRIALSARENA
CNS activates first European sites for glioblastoma multiforme trial
29 Sep 2022 //
CLINICALTRIALSARENA
CNS Pharma Bags Approval from FDA for Protocol Amendment to Trial of Berubicin
23 Jun 2022 //
PRNEWSWIRE
CNS to commence study of Berubicin for glioblastoma multiforme
29 Apr 2022 //
CLINICALTRIALSARENA
CNS Pharma Receives Approval for Pivotal Study of Berubicin in GBM
06 Apr 2022 //
PRNEWSWIRE
CNS Pharma Continues to Execute on Corporate, Clinical and Regulatory Strategies
01 Jul 2021 //
PR NEWSWIRE
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin
29 Jun 2021 //
PRNEWSWIRE
CNS Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin
17 Dec 2020 //
PRNEWSWIRE
CNS Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial
09 Nov 2020 //
PRNEWSWIRE
CNS Completes Manufacturing of Berubicin for Ph2 Clinical Trial
29 Oct 2020 //
PRNEWSWIRE
CNS Completes Manufacturing of Berubicin for Ph2 Clinical Trial
29 Oct 2020 //
PRNEWSWIRE
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin
20 Oct 2020 //
CONTRACTPHARMA
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Ph2 Trial
20 Oct 2020 //
PRNEWSWIRE
NCK A/S Receives CoA for Berubicin API
01 Oct 2020 //
CONTRACT PHARMA
CNS Pharmaceuticals Achieves Critical Manufacturing Milestone
01 Oct 2020 //
PRNEWSWIRE
CNS Pharmaceuticals & Image Analysis Group Partner for Development of Berubicin
24 Sep 2020 //
PRNEWSWIRE
CNS Achieves Key Milestones in Berubicin Dual-track Mfg. Strategy
04 Sep 2020 //
CONTRACTPHARMA
CNS Pharma completes manufacturing strategy for Berubicin to treat glioma
16 Jul 2020 //
PHARMABIZ
CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin
15 Jul 2020 //
PRNEWSWIRE
CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information
18 May 2020 //
PRNEWSWIRE
CNS Provides Additional Comments Regarding Trading Halt
11 May 2020 //
PR NEWSWIRE
CNS & WPD Identify Leading Polish Medical Institutions for Berubicin Ph2 Trial
30 Apr 2020 //
PRNEWSWIRE
CNS Pharma Announces Filing of FDA Orphan Drug Designation for Berubicin
23 Apr 2020 //
PR NEWSWIR
CNS Announces Shareholder Webinar to Discuss Collaboration with WPD Pharma
15 Apr 2020 //
PR NEWSWIRE
CNS Pharmaceuticals Announces Contract with International GMP Manufacturer
14 Jan 2020 //
PR NEWSWIRE
